FeesSafety
Pluang+

Achieve Life Sciences rebrands as AchieveRx, ticker QUIT, focusing on new FDA drug for quitting smoking and vaping

Market News
09 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Achieve Life Sciences rebrands as AchieveRx, ticker QUIT, focusing on new FDA drug for quitting smoking and vaping

Achieve Life Sciences has rebranded as AchieveRx, The Quit Company, and will trade under the new ticker QUIT starting November 10, 2026. The company is focused on developing cytisinicline, a potential first FDA-approved medicine in 20 years for smoking cessation and possibly the first for vaping cessation. Cytisinicline has shown promise in multiple Phase 3 trials involving difficult-to-treat smokers and a Phase 2 trial for vaping cessation. This rebranding aligns with the company's mission to help people quit nicotine through science-backed medicine as it moves toward commercial readiness.

Achieve Life Sciences' rebranding to AchieveRx, The Quit Company, is noted alongside Pluang's health sector market snapshot. For readers following health stocks, as of Nov 09, 2026 19:41 WIB, 121 of 150 priced US health-sector stocks rose while 18 fell. Notable movers include FLNA (Cassava Sciences Inc) at USD 0.48 with a 1-day change of +5.94% and a typical hold time on Pluang of 39 days, LFST (LifeStance Health Group Inc.) at USD 12.99 down -5.66% with a 12-day hold, and CLPT (ClearPoint Neuro Inc) at USD 8.99 up +4.53% with a 12-day hold.

More News

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...

Market News
Neutral
1 hour ago
New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...

Company Fundamentals
Bullish
2 hours ago
Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...

Bearish
2 hours ago
Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...

Market News
Bullish
2 hours ago
ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App